Moreover, the NAFLD activity score (NAS), a system of scoring the features of MASLD developed as a tool to measure changes in MASLD during therapeutic trials [47] (for more information see the methods section), was significantly increased in male CD1d−/− mice fed HFCD (Fig. 1e), as compared to the other groups. Here, CD1D is linked to metabolic dysfunction-associated steatotic liver disease.